Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From July 14, 2008 to August 29, 2008
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- up-and-down procedure
- Limit test:
- no
Test material
- Reference substance name:
- N-methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
- Cas Number:
- 1208319-26-9
- Molecular formula:
- C15H23N5O2S
- IUPAC Name:
- N-methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
Constituent 1
- Specific details on test material used for the study:
- Test material name in the study: PF-03394197-11
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Rationale for alternative/additional species to rat (if applicable)
- Source: Charles River Laboratories, Portage, Michigan
- Females (if applicable) nulliparous and non-pregnant: [yes/no]
- Rationale for use of males (if applicable)
- Age at study initiation: Approximately 7 weeks
- Weight at study initiation: Female: 184 to 273 g
- Fasting period before study: overnight
- Housing: Individually in stainless steel suspended wire mesh caging
- Historical data:
- Diet (e.g. ad libitum): Block Lab Diet® Certified Rodent Diet #5002, PMI Nutrition International, Inc. Ad libitum, except during designated periods.
- Water (e.g. ad libitum): Automatic watering system, Ad libitum, except during designated periods.
- Acclimation period: 7 to 32 Days
- Microbiological status when known
- Method of randomisation in assigning animals to test and control groups
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17.8 to 26.1°C
- Humidity (%): 30 to 70%
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): Fluorescent lighting was provided for approximately 12 hours per day.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- methylcellulose
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg
DOSAGE PREPARATION (if unusual):
The test article, was used as received from the Sponsor, and a correction
factor of 1.344 was applied to correct for the ratio of molecular weight of the salt to the base
of the test article. Dose preparation was performed by mixing the appropriate amount of test
article, with the appropriate amount of vehicle, to achieve the required nominal concentrations for the limit test, 200 mg/mL, and main tests, 17.5 and 55 mg/mL.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: limit dose level of 2000 mg/kg - Doses:
- 2000, 175, 550, 175, 550, 175, and 550 mg/kg
- No. of animals per sex per dose:
- 1 or 3 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for morbidity, mortality, injury, and the availability of food and water were conducted twice daily for all animals. Observations for clinical signs were conducted on each surviving animal at 0.5, 2, and 4 hours postdose on the day of dosing, and were continued once daily for no longer than 13 additional days, dependant on survival. Body weights were measured and recorded prior to test article administration on Day 1, and weekly thereafter. Additional body weights were taken for two animals found dead prior to submission to necropsy at dose levels of 2000 mg/kg and 550 mg/kg.
- Necropsy of survivors performed: Necropsy examinations were performed under procedures approved by a veterinary pathologist on all animals found dead, and all surviving animals at the scheduled necropsy. The surviving animals were euthanized by carbon dioxide inhalation, and euthanasia was confirmed by exsanguination via the abdominal vena cava. The animals were examined carefully for external abnormalities including masses. The skin was reflected from a ventral midline incision, and any abnormalities were identified and correlated with antemortem
findings. The abdominal, thoracic, and cranial cavities were examined for abnormalities, and the organs removed, examined, and the tissues and carcasses were discarded.
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 310.2 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All animals died on Day 2 at 2000 and 550 mg/kg dose level.
- Clinical signs:
- Impaired limb function, decreased activity, ataxia, slow and difficult breathing, salivation, lacrimation, and partially closed eyelids were observed following the limit dose of 2000 mg/kg, and prior to the animal being found dead. Impaired limb function, decreased activity, ataxia, slow and difficult breathing, prostration, hunched posture, salivation, skin cold to touch, red material around nose, lacrimation, and partially closed eyelids, and decreased feces were all observed in at least one of the three animals dosed at 550 mg/kg. Clinical findings observed following the administration at 550 and 2000 mg/kg were considered to be related to test article administration.
- Body weight:
- No effect of test article administration was observed on the body weights or body weight gains of the three animals at 175 mg/kg that survived to the scheduled necropsy on Day 15.
- Gross pathology:
- No test article-related macroscopic observations were made in study animals. Macroscopic observations were usual and/or incidental in rats of this type and age.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The oral LD50 of the test item when administered to female rats is estimated to be 310.2 mg/kg.
- Executive summary:
The acute oral study is performed according to OECD Guideline 425 under GLP. The oral LD50 of the test item when administered to female rats is estimated to be 310.2 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.